Peer-Reviewed Publication Reports on Medistem's Ongoing Phase II Trial SAN DIEGO, CA--(Marketwire - Mar 22, 2013) - Medistem Inc. ( PINKSHEETS : MEDS ) announced today it published an update on its RECOVER-ERC congestive heart failure Phase II clinical trial in a peer-reviewed journal (link to paper … [Read more...]
Medistem Inc. Appoints Biotechnology Veteran John Chiplin, Ph.D. to Board of Directors
January 8, 2013 By
SAN DIEGO, CA--(Marketwire - Jan 8, 2013) - Medistem Inc. ( PINKSHEETS : MEDS ), announced today that John Chiplin, Ph.D., has been elected to its Board of Directors. Dr. Chiplin has over 25 years of experience as a biopharmaceutical executive and is currently CEO of Polynoma, a Phase III cancer vaccine company. Dr. Chiplin is also on the Board of Directors of … [Read more...]
Medistem Inc. Annual Letter to Shareholders
January 4, 2013 By
Dear Fellow Shareholders, 2012 was marked by significant progress in the development of the Endometrial Regenerative Cell (ERC), our new universal donor "stem cell drug." Most significantly, we initiated a double blind, placebo controlled clinical study in patients with end stage heart failure, in which ERC were administered via the Medistem's patent-pending … [Read more...]
Urologic Surgery Pioneer Dr. Alexander Gershman Joins Medistem’s Scientific Advisory Board
November 19, 2012 By
Endometrial Stem Cell Company Expands Clinical Applications of Its Universal Donor Stem Cell Product SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Medistem ( PINKSHEETS : MEDS ) announced today appointment of Alexander Gershman, MD, Ph.D to the company's Scientific Advisory Board. Dr. Gershman is an internationally-renowned opinion leader in urological surgery … [Read more...]
Medistem CEO Dr. Alan Lewis to Present at the Stem Cell Meeting on the Mesa
October 26, 2012 By
Company to Discuss Clinical Trials using Menstrual Blood Derived Stem Cells for Treating Cardiovascular Disease SAN DIEGO--(BUSINESS WIRE)-- Medistem announced today Dr. Alan Lewis, the recently appointed CEO of Medistem, will be presenting at the Stem Cells on the Mesa meeting. The company will discuss its ongoing programs at creating effective treatments … [Read more...]
NIH Data Suggests Medistem’s Stem Cell is Unique from Competitor Stem Cells
October 10, 2012 By
SAN DIEGO--(BUSINESS WIRE)-- Medistem Inc. (PINKSHEETS: MEDS) announced today a peer-reviewed publication led by NIH scientists demonstrating that the company’s Endometrial Regenerative Cells (ERC) possess a unique genetic signature associated with production of new blood vessels (angiogenesis). “The demonstration by an independent group that ERC … [Read more...]
Biopharmaceutical Executive Dr. Alan Lewis Appointed as CEO of Medistem
October 8, 2012 By
World-Class Industry Expert to Accelerate Commercialization of Universal Donor Stem Cell Drug for Heart Failure, Critical Limb Ischemia and Type 1 Diabetes SAN DIEGO--(BUSINESS WIRE)-- Medistem Inc. (PINKSHEETS: MEDS) announced today appointment of Dr. Alan Lewis to the position of Chief Executive Officer and Member of the Board. Since January, Dr. Lewis has … [Read more...]
China Biotech In Review: Sanofi, Sinopharm To Conduct Joint Research Into Rare Diseases
October 7, 2012 By
Fosun Pharma's (SHA: 600196) long-in-the-works IPO on the Hong Kong exchange is scheduled to take place this month, raising a diminished $600 million. The company received regulatory approval for the offering five months ago, but market conditions have held the transaction back until now - and caused the company to drop the projected take from $800 million. There … [Read more...]
Medistem and Superview Biotechnology Co. Ltd. Initiate Collaboration on Therapeutics Development Using Antibody and Stem Cell Technology
October 1, 2012 By
SAN DIEGO--(BUSINESS WIRE)-- Medistem Inc (Pink Sheets:MEDS) announced today the initiation of a collaboration with Superview Biotechnology Co. Ltd, a subsidiary of Yinhuan Holding Co from Yixing, China. The joint work will be aimed at using proprietary stem cell lines developed by Medistem for screening of monoclonal antibodies for therapeutic activity in the … [Read more...]
Medistem to Provide Update on Heart Failure Clinical Trial at Noble Life Sciences Exposition
September 20, 2012 By
Adult Stem Cell Company Announces Presentation and Cell Therapy Panel Participation SAN DIEGO--(BUSINESS WIRE)-- Medistem Inc (Pink Sheets:MEDS), a clinical stage adult stem cell company, today announced that its CEO Dr. Thomas Ichim will attend and present at BIOX; Noble Financial Capital Markets’ Life Sciences Exposition to be held at the University of … [Read more...]